Journal
EXPERT OPINION ON EMERGING DRUGS
Volume 20, Issue 2, Pages 235-246Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728214.2015.1018176
Keywords
adjuvant; burns; chronic wounds; developing drugs; scarring; wound healing
Categories
Funding
- NIH [U01 HL099776, R01 DE021683-01, RC2 DE020771, GM087609, 1K08DE24269]
- Oak Foundation
- Hagey Laboratory for Pediatric Regenerative Medicine
- ACS Franklin H Martin Faculty research Fellowship
- Stanford University Child Health Research Institute Faculty Scholar award
Ask authors/readers for more resources
Introduction: Wound healing can be characterized as underhealing, as in the setting of chronic wounds, or overhealing, occurring with hypertrophic scar formation after burn injury. Topical therapies targeting specific biochemical and molecular pathways represent a promising avenue for improving and, in some cases normalizing, the healing process. Areas covered: A brief overview of both normal and pathological wound healing has been provided, along with a review of the current clinical guidelines and treatment modalities for chronic wounds, burn wounds and scar formation. Next, the major avenues for wound healing drugs, along with drugs currently in development, are discussed. Finally, potential challenges to further drug development, and future research directions are discussed. Expert opinion: The large body of research concerning wound healing pathophysiology has provided multiple targets for topical therapies. Growth factor therapies with the ability to be targeted for localized release in the wound microenvironment are most promising, particularly when they modulate processes in the proliferative phase of wound healing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available